Eligibility for percutaneous renal denervation: The importance of a systematic screening

Journal of Hypertension

Volumn 31, Issue 8, 2013, Pages 1662-1668

  Verloop, Willemien L ^a   Vink, Eva E ^a   Voskuil, Michiel ^a   Vonken, Evert Jan ^a   Rookmaaker, Maarten B ^a   Bots, Michiel L ^a   Doevendans, Pieter A ^a   Blankestijn, Peter J ^a   Spiering, Wilko ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

ambulatory blood pressure measurement; blood pressure; renal denervation; resistant hypertension; screening; secondary cause; white coat effect

Indexed keywords

ALDOSTERONE ANTAGONIST; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANTIHYPERTENSIVE AGENT; DIURETIC AGENT; RENIN INHIBITOR;

ADULT; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE MEASUREMENT; DIASTOLIC BLOOD PRESSURE; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY DENERVATION; MAJOR CLINICAL STUDY; MALE; MEAN ARTERIAL PRESSURE; PRIMARY HYPERALDOSTERONISM; PRIORITY JOURNAL; RENAL ARTERY; RESISTANT HYPERTENSION; SCREENING; SYSTOLIC BLOOD PRESSURE;

EID: 84880572288     PISSN: 02636352     EISSN: 14735598     Source Type: Journal    
DOI: 10.1097/HJH.0b013e328362152e     Document Type: Article

References (37)

1. Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: analysis of worldwide data. Lancet 2005; 365:217-223.
2. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002; 360:1903-1913.
3. Pereira M, Lunet N, Azevedo A, Barros H. Differences in prevalence, awareness, treatment and control of hypertension between developing and developed countries. J Hypertens 2009; 27:963-975.
4. Schlaich MP, Sobotka PA, Krum H, Whitbourn R, Walton A, Esler MD. Renal denervation as a therapeutic approach for hypertension: novel implications for an old concept. Hypertension 2009; 54: 1195-1201.
5. Schlaich MP, Sobotka PA, Krum H, Lambert E, Esler MD. Renal sympathetic-nerve ablation for uncontrolled hypertension. N Engl J Med 2009; 361:932-934.
6. Krum H, Schlaich M, Whitbourn R, Sobotka PA, Sadowski J, Bartus K, et al. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet 2009; 373:1275-1281.
7. Esler MD, Krum H, Sobotka PA, Schlaich MP, Schmieder RE, Bohm M. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet 2010; 376:1903-1909.
8. Symplicity HTN-1 Investigators. Catheter-based renal sympathetic denervation for resistant hypertension: durability of blood pressure reduction out to 24 months. Hypertension 2011; 57:911-917.
9. Schmieder RE, Redon J, Grassi G, Kjeldsen SE, Mancia G, Narkiewicz K, et al. ESH position paper: renal denervation: an interventional therapy of resistant hypertension. J Hypertens 2012; 30:837-841.
10. Calhoun DA, Jones D, Textor S, Goff DC, Murphy TP, Toto RD, et al. Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension 2008; 51:1403-1419.
11. Hajjar I, Kotchen TA. Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988-2000. JAMA 2003; 290:199-206.
12. Egan BM, Zhao Y, Axon RN. US trends in prevalence, awareness, treatment, and control of hypertension, 1988-2008. JAMA 2010; 303:2043-2050.
13. Sierra de la SA, Banegas JR, Oliveras A, Gorostidi M, Segura J, de la Cruz JJ, et al. Clinical differences between resistant hypertensives and patients treated and controlled with three or less drugs. J Hypertens 2012; 30:1211-1216.
14. Daugherty SL, Powers JD, Magid DJ, Tavel HM, Masoudi FA, Margolis KL, et al. Incidence and prognosis of resistant hypertension in hypertensive patients. Circulation 2012; 125:1635-1642.
15. Persell SD. Prevalence of resistant hypertension in the United States, 2003-2008. Hypertension 2011; 57:1076-1080.
16. Omura M, Saito J, Yamaguchi K, Kakuta Y, Nishikawa T. Prospective study on the prevalence of secondary hypertension among hypertensive patients visiting a general outpatient clinic in Japan. Hypertens Res 2004; 27:193-202.
17. Sukor N. Endocrine hypertension: current understanding and comprehensive management review. Eur J Intern Med 2011; 22: 433-440.
18. Viera AJ, Neutze DM. Diagnosis of secondary hypertension: an agebased approach. Am Fam Physician 2010; 82:1471-1478.
19. McManus RJ, Caulfield M, Williams B. NICE hypertension guideline 2011: evidence based evolution. BMJ 2012; 344:e181.
20. Banegas JR, Messerli FH, Waeber B, Rodriguez-Artalejo F, de la SA, Segura J, et al. Discrepancies between office and ambulatory blood pressure: clinical implications. Am J Med 2009; 122:1136-1141.
21. Waeber B, Brunner HR. Clinical value of ambulatory blood pressure monitoring in the assessment of antihypertensive therapy. Blood Press Monit 1999; 4:263-266.
22. Miyajima E, Yamada Y, Yoshida Y, Matsukawa T, Shionoiri H, Tochikubo O, et al. Muscle sympathetic nerve activity in renovascular hypertension and primary aldosteronism. Hypertension 1991; 17: 1057-1062.
23. Funder JW, Carey RM, Fardella C, Gomez-Sanchez CE, Mantero F, Stowasser M, et al. Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2008; 93:3266-3281.
24. Hiramatsu K, Yamada T, Yukimura Y, Komiya I, Ichikawa K, Ishihara M, et al. A screening test to identify aldosterone-producing adenoma by measuring plasma renin activity. Results in hypertensive patients. Arch Intern Med 1981; 141:1589-1593.
25. McKenna TJ, Sequeira SJ, Heffernan A, Chambers J, Cunningham S. Diagnosis under random conditions of all disorders of the reninangiotensin- aldosterone axis, including primary hyperaldosteronism. J Clin Endocrinol Metab 1991; 73:952-957.
26. Stowasser M, Gordon RD, Gunasekera TG, Cowley DC, Ward G, Archibald C, et al. High rate of detection of primary aldosteronism, including surgically treatable forms, after 'nonselective screening of hypertensive patients. J Hypertens 2003; 21:2149-2157.
27. Mantero F, Terzolo M, Arnaldi G, Osella G, Masini AM, Ali A, et al. A survey on adrenal incidentaloma in Italy. Study Group on Adrenal Tumors of the Italian Society of Endocrinology. J Clin Endocrinol Metab 2000; 85:637-644.
28. Pacak K, Linehan WM, Eisenhofer G, Walther MM, Goldstein DS. Recent advances in genetics, diagnosis, localization, and treatment of pheochromocytoma. Ann Intern Med 2001; 134:315-329.
29. Tombach B, Bremer C, Reimer P, Schaefer RM, Ebert W, Geens V, et al. Pharmacokinetics of 1M gadobutrol in patients with chronic renal failure. Invest Radiol 2000; 35:35-40.
30. Textor SC, Lerman L. Renovascular hypertension and ischemic nephropathy. Am J Hypertens 2010; 23:1159-1169.
31. Savard S, Frank M, Bobrie G, Plouin PF, Sapoval M, Azizi M. Eligibility for renal denervation in patients with resistant hypertension: when enthusiasm meets reality in real-life patients. J Am Coll Cardiol 2012; 60:2422-2424.
32. Muller O, Qanadli SD, Waeber B, Wuerzner G. Renal denervation in resistant hypertension: proposal for a common multidisciplinary attitude. Rev Med Suisse 2012; 8:1159-1163.
33. Mahfoud F, Vonend O, Bruck H, Clasen W, Eckert S, Frye B, et al. Expert consensus statement on interventional renal sympathetic denervation for hypertension treatment. Dtsch Med Wochenschr 2011; 136:2418.
34. Pathak A, Girerd X, Azizi M, Benamer H, Halimi JM, Lantelme P, et al. Expert consensus: renal denervation for the treatment of arterial hypertension. Arch Cardiovasc Dis 2012; 105:386-393.
35. Vink EE, Blankestijn PJ. Evidence and consequences of the central role of the kidneys in the pathophysiology of sympathetic hyperactivity. Front Physiol 2012; 3:29.
36. Blankestijn PJ, Ritz E. Renal denervation: potential impact on hypertension in kidney disease? Nephrol Dial Transplant 2011; 26:2732-2734.
37. Yiannakopoulou EC, Papadopulos JS, Cokkinos DV, Mountokalakis TD. Adherence to antihypertensive treatment: a critical factor for blood pressure control. Eur J Cardiovasc Prev Rehabil 2005; 12: 243-249.